abstract |
The present invention relates to TPH2 gene polymorphism rs4760815, SLC6A4 gene polymorphism 5-HTTLPR, SLC6A4 gene polymorphism rs2066713, GAD1 gene polymorphism rs3828275 and GRIK2 gene polymorphism rs543196 to provide information on the therapeutic effect of SSRI antidepressants. Accordingly, antidepressants can be selected according to genetic information, early detection of deterioration and recurrence of depression, effective in developing new drugs, and establishment of a customized treatment model for depression suitable for Koreans. In addition, by expanding the domestic clinical trial base, it is possible to secure competitiveness in the pharmaceutical market and preoccupy the technology for drug prediction. |